Purpose: To assess the attitudes and behaviors of physicians, hospital pharmacists, registered nurses, and other healthcare professionals toward naloxone use. This survey will help the University Medical Center New Orleans Analgesic Management Stewardship team understand barriers and determine the education needed to improve the care we provide.
Methods: A survey was conducted at a single center, and it contained 17 questions: two concerning provider type and practice setting, followed by 15 qualitative questions to be answered in a Likert scale format, with options ranging from strongly disagree to strongly agree. The survey was disseminated via email, in person, and at meetings. A quick-response code was used.
Results: The total number of participants in the survey was 151. Physicians accounted for the majority (n = 76, 50.3 percent), followed by registered nurses (n = 36, 23.8 percent) and then pharmacists (n = 17, 11.3 percent). Respondents primarily practiced in an inpatient medicine service (n = 78, 51.7 percent). When evaluating the impact naloxone has on patients suffering from opioid use disorder (OUD), most participants acknowledged that naloxone has an important part in treatment (n = 135, 89.4 percent) and has a positive impact on these patients (n = 129, 85.4 percent). Inappropriate naloxone use was addressed. A minority of the participants (n = 13, 8.6 percent) agreed that OUD patients would not use naloxone appropriately, with 38 (25.2 percent) participants remaining neutral. Furthermore, this response more than doubled (n = 29, 19.2 percent) for those who at least agreed that naloxone would only increase opioid use and risky behavior. While a majority felt comfortable educating their patients on naloxone use (n = 103, 68.2 percent), only about half of the total respondents (n = 79, 52.3 percent) stated that they have received training on naloxone use for OUD patients. Just over half of the participants of this survey (n = 77, 51 percent) reported being aware of the standing order status of naloxone in Louisiana.
Conclusions: Based on the responses, there is a consensus that naloxone is effective and an important part of treatment for OUD patients. However, barriers exist where participants may not have received training or may not be comfortable educating patients on naloxone. In addition, there is concern among participants that patients may not use naloxone appropriately.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5055/jom.0879 | DOI Listing |
Drug Alcohol Depend Rep
March 2025
Institute for Drug and Alcohol Studies, Virginia Commonwealth University, 203 East Cary Street, Richmond, VA 23219, USA.
Background: Evidence supports the common incidence of sleep disturbance in opioid use disorder (OUD) as a potential marker of disrupted orexin system functioning. This study evaluated the initial safety and tolerability of a challenge dose of lemborexant, a dual orexin antagonist, as an adjunct to buprenorphine/naloxone.
Methods: Patients (18-65 years old) with OUD receiving sublingual buprenorphine/naloxone, with a Pittsburgh Sleep Quality Index total score of 6 or higher, were recruited from outpatient clinics.
Turk J Pharm Sci
January 2025
Shahid Beheshti University of Medical Sciences Faculty of Medicine, Toxicological Research Center, Excellence Center and Department of Clinical Toxicology, Tehran, Iran.
Objectives: Constipation caused by opioid-induced constipation (OIC) is prevalent among critically poisoned patients and can result in complications that prolong hospitalization and, in rare cases, cause bowel perforatio This research aimed to evaluate the safety and efficacy of lactulose and naloxone in the treatment of OIC in the intensive care unit for poisoning.
Materials And Methods: This was a randomized, double-blind, clinical trial of patients with opioid poisoning who experienced constipation for 14 months. Patients were divided into two groups: one receiving lactulose (30 cc daily) and the other receiving naloxone (8 mg three times a day).
HCA Healthc J Med
December 2024
HCA Florida Orange Park Hospital, Orange Park, FL.
Introduction: As illicit drug manufacturers find new ways to market their products and increase their profit margins, multiple contaminants have found their way into the illicit drug supply. The newest addition, xylazine, also known as "tranq," has spread through the city of Philadelphia and has recently been gaining ground across the United States, including in the state of Florida.
Case Presentation: This case describes a 37-year-old male with a significant past psychiatric history of severe polysubstance intravenous (IV) use, including fentanyl and methamphetamine.
Prehosp Emerg Care
January 2025
Department of Emergency Medicine, MetroHealth Medical Center, Cleveland, OH.
Objectives: Opioid-associated fatal and non-fatal overdose rates continue to rise. Prehospital overdose education and naloxone distribution (OEND) programs are attractive harm-reduction strategies, as patients who are not transported by EMS after receiving naloxone have limited access to other interventions. This narrative summary describes our experiences with prehospital implementation of evidence-based OEND practices across Ohio as part of the HEALing Communities Study (HCS).
View Article and Find Full Text PDFPrehosp Emerg Care
January 2025
Wake County Emergency Medical Services, 331 S. McDowell St, Raleigh, NC 27601.
Objectives: Buprenorphine has recently emerged as a prehospital treatment for opioid use disorder. Limited data exist regarding the implementation of prehospital buprenorphine programs. Our objective was to describe the development, deployment, lessons learned, and ongoing evolution of the Wake County EMS buprenorphine program using data from the first year following implementation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!